Business
First subject dosed in COVIDITY clinical trial
First subject dosed in COVIDITY clinical trial.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 1072O\n Scancell Holdings Plc\n 05 October 2021\n \n \n \n 5th October 2021\n \n Scancell Holdings plc\n (\"Scancell\" or the \"Company\")\n \n First subject dosed in COVIDITY Phase 1 clinical trial in South Africa\n \n Novel bivalent COVID-19 vaccine based on ImmunoBody® DNA vaccine technology\n \n SCOV1 administered using clinically proven PharmaJet Needle-free Injection System\n \n \n Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces that the first subject has been dosed in its COVIDITY clinical trial being conducted at the University of Cape Town (UCT) Lung Institute in South Africa. The COVIDITY programme is a collaboration between Scancell and scientists in the newly established Centre for Research on Global Virus Infections and the new Biodiscovery Institute at the University of Nottingham, and Nottingham Trent University and the programme has received funding from Innovate UK.\n \n The objectives of Part 1 of the trial are to assess the safety and immunogenicity of two vaccine candidates, SCOV1 and SCOV2, which target the original and variant SAR-CoV-2 viruses, respectively, in healthy, vaccine-naïve subjects. The study will determine the immunological responses induced by the vaccines administered by two alternative injection routes using two PharmaJet needle-free delivery systems. In addition to measuring virus neutralising antibodies (VNAbs) induced by the viral spike (S) protein, the Company will also analyse the T cell responses to the highly-conserved nucleocapsid (N) protein, which will provide further information and data on the potential utility of both SCOV1 and SCOV2 against future SARS-CoV-2 variants, including the Delta variant.\n \n SCOV1 and SCOV2 are based on a modification of Scancell's ImmunoBody® DNA vaccine technology and have a dual mechanism of action to induce high avidity T-cell immune responses against both the N and S viral antigens. After demonstration of safety in the South African part of the study, the Company plans to seek approval from the Medicines & Healthcare products Regulatory Agency (MHRA) to initiate a UK extension of the study, in which COVIDITY will be given to healthy volunteers who have already received two...